Cargando…
Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA
HIV-1 replication can be efficiently inhibited by intracellular expression of an siRNA targeting the viral RNA. We used a well-validated siRNA (si510) which targets the poly A/TAR (transactivator of the HIV-1 LTR) site and suppresses viral replication. Nanotechnology holds much potential for impact...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108557/ https://www.ncbi.nlm.nih.gov/pubmed/21660279 http://dx.doi.org/10.4061/2011/719139 |
_version_ | 1782205328561012736 |
---|---|
author | Mahajan, Supriya D. Aalinkeel, Ravikumar Reynolds, Jessica L. Nair, Bindukumar Sykes, Donald E. Law, Wing-Cheung Ding, Hong Bergey, Earl J. Prasad, Paras N. Schwartz, Stanley A. |
author_facet | Mahajan, Supriya D. Aalinkeel, Ravikumar Reynolds, Jessica L. Nair, Bindukumar Sykes, Donald E. Law, Wing-Cheung Ding, Hong Bergey, Earl J. Prasad, Paras N. Schwartz, Stanley A. |
author_sort | Mahajan, Supriya D. |
collection | PubMed |
description | HIV-1 replication can be efficiently inhibited by intracellular expression of an siRNA targeting the viral RNA. We used a well-validated siRNA (si510) which targets the poly A/TAR (transactivator of the HIV-1 LTR) site and suppresses viral replication. Nanotechnology holds much potential for impact in the field of HIV-1 therapeutics, and nanoparticles such as quantum rods (QRs) can be easily functionalized to incorporate siRNA forming stable nanoplexes that can be used for gene silencing. We evaluated the efficacy of the QR-si510 HIV-1 siRNA nanoplex in suppressing viral replication in the HIV-1-infected monocytic cell line THP-1 by measuring p24 antigen levels and gene expression levels of HIV-1 LTR. Our results suggest that the QR-si510 HIV-1 siRNA nanoplex is not only effective in delivering siRNA, but also in suppressing HIV-1 viral replication for a longer time period. HIV-1 nanotherapeutics can thus enhance systemic bioavailability and offer multifunctionality. |
format | Online Article Text |
id | pubmed-3108557 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | SAGE-Hindawi Access to Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-31085572011-06-09 Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA Mahajan, Supriya D. Aalinkeel, Ravikumar Reynolds, Jessica L. Nair, Bindukumar Sykes, Donald E. Law, Wing-Cheung Ding, Hong Bergey, Earl J. Prasad, Paras N. Schwartz, Stanley A. Patholog Res Int Research Article HIV-1 replication can be efficiently inhibited by intracellular expression of an siRNA targeting the viral RNA. We used a well-validated siRNA (si510) which targets the poly A/TAR (transactivator of the HIV-1 LTR) site and suppresses viral replication. Nanotechnology holds much potential for impact in the field of HIV-1 therapeutics, and nanoparticles such as quantum rods (QRs) can be easily functionalized to incorporate siRNA forming stable nanoplexes that can be used for gene silencing. We evaluated the efficacy of the QR-si510 HIV-1 siRNA nanoplex in suppressing viral replication in the HIV-1-infected monocytic cell line THP-1 by measuring p24 antigen levels and gene expression levels of HIV-1 LTR. Our results suggest that the QR-si510 HIV-1 siRNA nanoplex is not only effective in delivering siRNA, but also in suppressing HIV-1 viral replication for a longer time period. HIV-1 nanotherapeutics can thus enhance systemic bioavailability and offer multifunctionality. SAGE-Hindawi Access to Research 2011-05-10 /pmc/articles/PMC3108557/ /pubmed/21660279 http://dx.doi.org/10.4061/2011/719139 Text en Copyright © 2011 Supriya D. Mahajan et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Mahajan, Supriya D. Aalinkeel, Ravikumar Reynolds, Jessica L. Nair, Bindukumar Sykes, Donald E. Law, Wing-Cheung Ding, Hong Bergey, Earl J. Prasad, Paras N. Schwartz, Stanley A. Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA |
title | Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA |
title_full | Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA |
title_fullStr | Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA |
title_full_unstemmed | Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA |
title_short | Nanotherapeutics Using an HIV-1 Poly A and Transactivator of the HIV-1 LTR-(TAR-) Specific siRNA |
title_sort | nanotherapeutics using an hiv-1 poly a and transactivator of the hiv-1 ltr-(tar-) specific sirna |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108557/ https://www.ncbi.nlm.nih.gov/pubmed/21660279 http://dx.doi.org/10.4061/2011/719139 |
work_keys_str_mv | AT mahajansupriyad nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna AT aalinkeelravikumar nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna AT reynoldsjessical nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna AT nairbindukumar nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna AT sykesdonalde nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna AT lawwingcheung nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna AT dinghong nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna AT bergeyearlj nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna AT prasadparasn nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna AT schwartzstanleya nanotherapeuticsusinganhiv1polyaandtransactivatorofthehiv1ltrtarspecificsirna |